NUVB News and Press, Nuvation Bio Inc. Class A From 01/10/22

Nuvation Bio Provides Corporate Update and Highlights Key 2022 Milestones PR Newswire David Hung , M.D., founder, president, and chief executive officer, to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022 at 7:30 a.m...

Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies - Adds Mike Powell, Ph.D., as Executive Partner & promotes Francesco Draetta to Partner PR Newswire BOSTON , Dec. 17, 2021 /PRNewswire/ -- Omega F...

Nuvation Bio (NYSE:NUVB) announced that the FDA granted its Fast Track designation to the company’s lead drug candidate NUV-422 for the treatment of high-grade gliomas, including glioblastoma multiforme. The Fast Track designation is offered by the regulator to accelerate the developme...

Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma Multiforme PR Newswire NEW YORK , Dec. 15, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company t...

Shares of Nuvation Bio (NUVB +3.7%) are higher this morning after the FDA cleared an IND application for NUV-422 for prostate cancer. In December 2020, the company began a phase 1/2 study of NUV-422 for high grade gliomas, later amending the protocol to include HR+/HER2- advanced breast cance...

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostate Cancer PR Newswire NEW YORK , Dec. 13, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling so...

Nuvation Bio (NYSE:NUVB) is trading ~3.1% higher in the pre-market after the company announced that the FDA cleared its investigational new drug (IND) application for NUV-422 as a potential therapy for advanced breast cancer. FDA has already cleared its previous IND application to test NUV-42...

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Advanced Breast Cancer PR Newswire NEW YORK , Dec. 8, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of t...

David Abrams’ 13F portfolio value increased marginally this quarter from $4.50B to $4.59B. The number of positions increased from 16 to 18. Abrams Capital Management added Tempur Sealy International and Coupang during the quarter. The top three positions are Lithia Motors, ...

David Einhorn's 13F stock portfolio value decreased from $1.59B to $1.49B this quarter. Greenlight increased The ODP Group, LivaNova plc, and Sonos while reducing Concentrix and AerCap Holdings. The largest three positions are at ~44% of the portfolio. As of Q3 2021, the overall p...